Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i>

Victoria Clark(Yale Cancer Center), E. Zeynep Erson‐Omay(Yale Cancer Center), Akdes Serin(Yale Cancer Center), Jun Yin(Yale University), Justin Cotney(Yale University), Koray Özduman(Acıbadem University), Timuçin Avşar(Istanbul Technical University), Jie Li(Yale University), Phillip B. Murray(Yale Cancer Center), Octavian Henegariu(Yale Cancer Center), Saliha Yılmaz(Yale Cancer Center), Jennifer Moliterno Günel(Memorial Sloan Kettering Cancer Center), Geneive Carrión-Grant(Yale Cancer Center), Baran Yılmaz(Marmara University), Conor Grady(Yale Cancer Center), Bahattin Tanrıkulu(Marmara University), Mehmet Bakırcıoğlu(Yale Cancer Center), Hande Kaymakçalan(Bahçeşehir University), Ahmet Okay Çağlayan(Yale Cancer Center), Leman Sencar(Yale Cancer Center), Emre Ceyhun(Yale Cancer Center), Ahmet Atik(Marmara University), Yaşar Bayri(Marmara University), Hanwen Bai(Yale Cancer Center), Luis Kolb(Yale Cancer Center), Ryan Hebert(Yale Cancer Center), Sacit Bulent Omay(Yale Cancer Center), Ketu Mishra-Gorur(Yale Cancer Center), Murim Choi(Yale University), John D. Overton(Yale University), Eric C. Holland(Memorial Sloan Kettering Cancer Center), Shrikant Mane(Yale University), Matthew W. State(Yale University), Kaya Bilgüvar(Yale Cancer Center), Joachim M. Baehring(Yale Cancer Center), Philip H. Gutin(Memorial Sloan Kettering Cancer Center), Joseph M. Piepmeier(Yale Cancer Center), Alexander O. Vortmeyer(Yale University), Cameron Brennan(Memorial Sloan Kettering Cancer Center), M. Necmettin Pamir(Acıbadem University), Türker Kılıç(Bahçeşehir University), Richard P. Lifton(Howard Hughes Medical Institute), James P. Noonan(Yale University), Katsuhito Yasuno(Yale Cancer Center), Murat Günel(Yale Cancer Center)
Science
January 25, 2013
Cited by 880Open Access
Full Text

Abstract

We report genomic analysis of 300 meningiomas, the most common primary brain tumors, leading to the discovery of mutations in TRAF7, a proapoptotic E3 ubiquitin ligase, in nearly one-fourth of all meningiomas. Mutations in TRAF7 commonly occurred with a recurrent mutation (K409Q) in KLF4, a transcription factor known for its role in inducing pluripotency, or with AKT1(E17K), a mutation known to activate the PI3K pathway. SMO mutations, which activate Hedgehog signaling, were identified in ~5% of non-NF2 mutant meningiomas. These non-NF2 meningiomas were clinically distinctive-nearly always benign, with chromosomal stability, and originating from the medial skull base. In contrast, meningiomas with mutant NF2 and/or chromosome 22 loss were more likely to be atypical, showing genomic instability, and localizing to the cerebral and cerebellar hemispheres. Collectively, these findings identify distinct meningioma subtypes, suggesting avenues for targeted therapeutics.


Related Papers